LinkBlog
Gateway to PTSD information
Smoking, giving up and mental health - doses of some psych drugs may need to be adjusted
How can I stop smoking? What works, what doesn't? (PDF)
Blue Star Mothers of America's Guide to PTSD (pdf)
blog roll
- Agoraphobia
- Anxiety 2 Calm
-
Anxious Living : An Exploration
into Social Anxiety - Dare to Dream
- Dear Tobacco
-
Dr. Deborah Serani's:
Psychological Perspectives - Fast Weight Loss?
- Finding the Confidence
- GNIF Brain Blogger
- Legacy of War
- Mental Health Minutes
- Neurophilosophy
- PTSD Combat
- The Happiness Guy
- The Last Psychiatrist
- The Trouble With Spikol
-
WebMD: Anxiety and
Stress Management - We Worry: A Blog for the Anxious
recommended links
Depression Is Real Coalition
-
ABIL: Agoraphobics Building
Independant Lives -
Agoraphobia and Panic
Disorder Foundation -
Anxiety Disorders Association
of America - Anxiety Network Australia
- Anxiety-Panic.Com
- AnxietyZone
- Army Behavioral Health
- BrainPhysics - OCD
-
Canadian Network for Mood
and Anxiety Treatments - Children of Hoarders
- Choices in Mental Health (UK)
-
Dart Foundation: Gateway to PTSD
information -
David Baldwin's
Trauma Information Pages - EMDR Institute, Inc.
- EMDR Network Japan
- Fear of Flying course (free)
- Healthy Minds
- Information for People with Anxiety Disorders
- Internet Guide to REBT, CBT
- Living with a Brain Disorder
- Morita Therapy
- Mayo Clinic : Depression
- Mayo Clinic : GAD
- Mayo Clinic : OCD
- Mayo Clinic : Panic Attacks
- Mayo Clinic : PTSD
- Mayo Clinic : Social Anxiety
-
Medicines.org.uk - Anxiety &
Depression guides - Mind-Your-Mind Canada
- National Center for PTSD
-
National Institute of Mental
Health (NIMH) - No Such Thing As Crazy
- OCD Action, UK
- OCD Ireland
- Obsessive Compulsive Foundation
- Open Minds, Open Doors
- Paniccure.com
- Partners With PTSD
- Prescription Drug Information
- Psychiatric Service Dog Society
-
Rational Emotive Behavior
Therapy (REBT) - Sane Australia
-
Shyness & Social Anxiety
Service of Australia -
Social Phobia/Social Anxiety
Association - Social Anxiety Support board
-
South African Depression &
Anxiety Group - Suicide Prevention Help
-
tAPir - the Anxiety Panic
internet resource -
The Panic Center (Free
CBT based programs) - The School of OCD
- UN-WHO Drug Trials Database
- U.S. Army Behavioral Health - PTSD
"just don't smoke"
"Don't smoke, whatever you do, just don't smoke."
Yul Brynner
Yul Brynner
- Menthol cigarettes harder to quit
- Secondhand smoke in cars serious threat to kid's health
- Starting smoking young increases addiction risk
-
Smoking doesn't slim girls;
stunts boys' growth - 40 reasons why you should quit smoking
- Pregnant smokers 'prime' their kids to smoke
- Smoking related coronary artery disease quickly reversed if young smokers quit
- Not ready to quit? Try cutting back
- Half smoking again within year of lung cancer surgery
- Cutting back 'compensation' increases toxin load per cigarette
- Tobacco companies upped nicotine level 11% since 1998
- Workplace passive smoke increases lung cancer risk
- Hooked by genes: The DNA sequences cigarette companies love
- Smoking causes long lasting changes to brain's bio chemistry
- Nicotine receptor stimulant trebles the odds of stopping smoking
- Bupropion, nortriptyline double chances of quitting
- Nicotine's powerful role in reinforcing smoking
- Pregnant smokers raise child's risk of stroke, heart attack
- Smoking linked to pancreatic cancer
- Neurobiology of Smokers' Cravings
- 'Low cancer risk' cigarettes as deadly as regular kind
- Quitting reduces lung cancer death risk by 70%
- Fetal nicotine exposure linked to teen attention problems
- Outdoor second-hand smoke exposure can harm
- Response to day's first cigarette predicts ease of quitting
- 'Healthy' children of smoking parents aren't really so healthy
- Children of smokers have up to five times higher levels of a nicotine toxin
- Smoking increases risk of dementia
- Smoking kills even after quitting
- Antenatal second hand smoke exposure increases child's psychological problems
- Smoking could kill 1 billion this century: WHO
- Just 1 cigarette can lead to nicotine addiction
- Smokers less likely to survive early stage lung cancer
anti torture campaign
- Torture experts write APA policy
- [APA] still rocked by torture debate
- Petition for psychologists
- AMA president says APA "did not accurately represent our ethical guidelines"
- Psychologists Aiding Torturers
-
Annual conference endorses
APA's torture policy :( - Physicians for Human Rights call on Congress to vote No on Military Commissions Bill
-
Torture is a Form of Trauma;
Trauma Causes PTSD - Psychoanalysts' association condemns torture use
- Humiliating, inhumane or degrading treatment IS torture
- Two American psychologists accused of war crimes. U.S. DoD investigating.
Deputy Army Chief of Staff for Intelligence, Lt. General John (Jeff) Kimmons, has stated that no actionable intelligence had been obtained through abusive interrogation methods in the last 5 years.
monument, Monmouth County
New Jersey.
Novartis and Servier reach agreement on novel Major Depression drug
posted Thursday, 30 March 2006
Novartis And Servier Reach Agreement On Novel Major Depression Drug
Basel, Switzerland, March 29, 2006 - Novartis and Servier announced today the signing of a licensing agreement for agomelatine, a Phase III investigational drug for the treatment of major depressive disorder, a condition estimated to affect one in ten adults in the US alone.Under development as a once-daily treatment, agomelatine is a novel melatonergic antidepressant that acts as an agonist at MT1 and MT2 receptors with additional 5-HT2c antagonist properties. Due to its unique receptor profile, agomelatine represents a potential innovation for the pharmacological treatment of depression.
The efficacy, tolerability and safety of agomelatine has been assessed in several double-blind, randomized, placebo- and active-controlled Phase III studies conducted by Servier, mainly in Europe, Canada and Australia. In the active-controlled studies, which utilized a commonly prescribed product for the treatment of major depression, the effect of agomelatine was similar to that of the active-control.
In general, the number of adverse events experienced in patients treated with agomelatine during these studies was comparable to placebo. The main adverse events were dizziness, headache and nausea1. Additionally, the tolerability and safety profile of agomelatine includes a lack of clinically significant weight gain, no apparent effects on sexual function (particularly as compared with the active-control), a low incidence of gastro-intestinal adverse events as well as absence of discontinuation symptoms upon withdrawal 1,2,3,4.
References:
-
Rouillon F,
Efficacy and tolerance profile of agomelatine and practical use in depressed patients.
Int Clin Psychopharmacol. 2006;21 Suppl 1:31-5 [Abstract]
-
Loo H, Hale A, D'haenen H.
Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.
Int Clin Psychopharmacol. 2002;17(5):239-47. [Abstract]
-
Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I.
Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.
Int Clin Psychopharmacol. 2004;19(5):271-80. [Abstract]
- Kennedy SH, Emsley R.
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.
Eur Neuropsychopharmacol. 2006 16:93-100. [Abstract]
Comment:
Agomelatine has also shown anti anxiety properties:
Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety.
Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCN.
Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.
Agomelatine has also shown anti anxiety properties:
Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety.
Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCN.
Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.
comments (1)
1. LOUISE LONSDALE left...
Friday, 9 February 2007 10:10 pm
i have been involved in the phase 3 drug trial for agomelatine and found it to be as good as ssri but without the bad side effects eg. libido problems and lethargy